Elegant analyses of patients with TP53-mutated MDS demonstrated that approximately 40% of the population harbors disease with a copy-neutral loss of heterozygosity, which, based on the predicted absence of the functional TP53 protein, was significantly associated with inferior survival; conversely, patients with a monoallelic loss of TP53 fared similar to patients with TP53 wild-type disease [29]. Here, TP53 is linked to myelodysplastic syndrome.